SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-21-013102
Filing Date
2021-02-05
Accepted
2021-02-05 17:17:12
Documents
3
Group Members
NOVARTIS AG

Document Format Files

Seq Description Document Type Size
1 SC 13G tm215202d2_sc13g.htm SC 13G 63846
2 EXHIBIT 99.1 tm215202d2_ex99-1.htm EX-99.1 11370
3 EXHIBIT 99.2 tm215202d2_ex99-2.htm EX-99.2 5499
  Complete submission text file 0001104659-21-013102.txt   82284
Mailing Address 250 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139
Business Address 250 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139 (617) 871-8000
Novartis Institutes for BioMedical Research, Inc. (Filed by) CIK: 0001673852 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G

Mailing Address 1313 N. MARKET STREET SUITE 5100 WILMINGTON DE 19801
Business Address 1313 N. MARKET STREET SUITE 5100 WILMINGTON DE 19801 (857) 444-0553
Ayala Pharmaceuticals, Inc. (Subject) CIK: 0001797336 (see all company filings)

IRS No.: 823578375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-91506 | Film No.: 21597261
SIC: 2836 Biological Products, (No Diagnostic Substances)